1. Lee T.W.R., Brownlee K.G., Conway S.P. et al. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J. Cyst. Fibros. 2003; 2 (1): 29-34. https://doi.org/10.1016/S1569-1993(02)00141-8.
2. Morton R., Doe S., Banya W. et al. Clinical benefit of continuous nebulised Aztreonam Lysine for Inhalation (AZLI) in adults with cystic fibrosis - a retrospective cohort study. J. Cyst. Fibros. 2017; 16 (Suppl. 1): S55. Available at: https://www.cysticfibrosisjournal.com/article/S1569-1993(17)30340-5/pdf
3. Smyth A.R., Bell S.C., Bojcin S. et al. European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. J. Cyst. Fibros. 2014; 13 (Suppl. 1): S23-42. https://doi.org/10.1016/j.jcf.2014.03.010.
4. Castellani C., Duff A.J.A., Bell S.C. et al. ECFS best practice guidelines: the 2018 revision. J. Cyst. Fibros. 2018; 17 (2): 153-178. https://doi.org/10.1016/j.jcf.2018.02.006.
5. Ratjen F., Munck A., Kho P. et al. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax. 2010; 65 (4): 286-291. https://doi.org/10.1136/thx.2009.121657.
6. Taccetti G., Bianchini E., Cariani L. et al. Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols. Thorax. 2012; 67 (10): 853-859. https://doi.org/10.1136/thoraxjnl-2011-200832.
7. Proesmans M., Vermeulen F., Boulanger L. et al. Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis. J. Cyst. Fibros. 2013; 12 (1): 29-34. https://doi.org/10.1016/j.jcf.2012.06.001.
8. Döring G., Flume P., Heijerman H. et al. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J. Cyst. Fibros. 2012; 11 (6): 461-479. https://doi.org/10.1016/j.jcf.2012.10.004.
9. Smith S., Rowbotham N.J., Regan K.H. Inhaled anti- pseudomonal antibiotics for long-term therapy in cystic fibrosis. Cochrane Database Syst. Rev. 2018; (3): CD001021. https://doi.org/10.1002/14651858.CD001021.pub3.
10. Pierart F. [TOBI Podhaler for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis patients]. Rev. Med. Liege. 2013; 68 (9): 486-488 (in French).
11. Hodson M.E., Gallagher C.G., Govan J.R.W. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur. Respir. J. 2002; 20 (3): 658-664. https://doi.org/10.1183/09031936.02.00248102.
12. Chuchalin A., Csiszér, E., Gyurkovics K. et al. A formulation of aerosolized tobramycin (Bramitob®) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo- controlled, multicenter study. Pediatr. Drugs. 2007; 9 (Suppl. 1): 21-31. https://doi.org/10.2165/00148581-200709001-00004.
13. Konstan M.W., Flume P.A., Keppler M. et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J. Cyst. Fibros. 2011; 10 (1): 54-61. https://doi.org/10.1016/j.jcf.2010.10.003.
14. Pisarev V.V. [Comparison of antibacterial activities of tobramycin inhalation solutions]. Antibiotiki i khimioterapiya. 2013; 58 (3-4): 19-21. Available at: https://www.antibiotics-chemotherapy.ru/jour/article/view/478/478 (in Russian).
15. Gorinova Yu.V., Simonova O. I., Lazareva A. V. et al. [Experience of long-term use of tobramycin solution inhalations in chronic Pseudomonas aeruginosa infection in children with cystic fibrosis]. Rossiyskiy pediatricheskiy zhurnal. 2015; 18, (3): 50-53. Available at: https://cyberleninka.ru/article/n/opyt-dlitelnogo-primeneniya-ingalyatsiy-rastvora-tobramitsina-pri-hronicheskoy-sinegnoynoy-infektsii-u-detey-s-mukovistsidozom/viewer (in Russian).
16. Chepurnaya M.M., Yagubyants E.T., Kharakhash’yan L.E. et al. [Inhaled tobramycin for hospital treatment of children with cystic fibrosis]. Prakticheskaya pul’monologiya. 2017; (1): 42-44. Available at: https://cyberleninka.ru/article/n/opyt-primeneniya-ingalyatsionnogo-tobramitsina-u-detey-s-mukovistsidozom-v-usloviyah-statsionara/viewer (in Russian).
17. Golubtsova O.I., Gorinova Yu.V., Krasnov M.V. et al. [Inhaled tobramycin for the treatment of chronic pseudomonas aeruginosa infection in children with cystic fibrosis in the Chuvash Republic]. Prakticheskaya pul’monologiya. 2017; (3): 40-45. Available at: https://cyberleninka.ru/article/n/opyt-primeneniya-ingalyatsionnogo-tobramitsina-pri-hronicheskoy-sinegnoynoy-infektsii-u-detey-s-mukovistsidozom-v-chuvashskoy/viewer (in Russian).
18. Pavlinova E.B., Mingairova A.G., Safonova T.I. et al. [Clinical significance of lung microbiota and experience of the inhaled antibacterial therapy in children of the Omsk Cystic Fibrosis Center (sase series)]. Pediatricheskaya farmakologiya. 2018; 15 (2): 121-128. https://doi.org/10.15690/pf.v15i2.1868 (in Russian).
19. [Cystic fibrosis: clinical guidelines. 2020]. Available at: http://cr.rosminzdrav.ru/recomend/372_1 (in Russian).
20. Quanjer P.H., Tammeling G.J., Cotes J.E. et al. Lung volumes and forced ventilatory flows. Eur. Respir. J. 1993; 6 (16): 5-40. https://doi.org/10.1183/09041950.005s1693.
21. Huskisson E.C. Measurement of pain. Lancet. 1974; 304 (7889): 1127-1131. https://doi.org/10.1016/s0140-6736(74)90884-8.
22. Solyanik E.V. [Use of psychometric visual analog scales in assessing of the severity of stable angina pectoris and the effectiveness of antianginal therapy]. Ratsional’naya farmakoterapiya v kardiologii. 2011; 7 (5): 591-595. Available at: https://cyberleninka.ru/article/n/ispolzovanie-psihometricheskih-vizualno-analogovyh-shkal-v-otsenke-stepeni-tyazhesti-stabilnoy-stenokardii-i-effektivnosti/viewer (in Russian).
23. Polikarpova S.V., Kondratyeva E.I., Shabalova L.A. et al. [Microflora of the respiratory tract in patients with cystic fibrosis and sensitivity to antibiotics based on a 15-year follow-up (2000-2015 years)]. Meditsinskiy sovet. 2016; (15): 84-89. https://doi.org/10.21518/2079-701X-2016-15-84-89 (in Russian).
24. Shaginyan I.A., Avetisyan L.R., Chernukha M.Yu. et al. [Epidemiological significance of genome variations in Pseudomonas aeruginosa causing chronic lung infection in patients with cystic fibrosis]. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya. 2019; 21 (4): 340-351. https://doi.org/10.36488/cmac.2019.4.340-351 (in Russian).
25.
26.